LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (publ) (OMXS: BINV) today announced that the company’s Board of Directors decided, after the closing of trading at NASDAQ OMX Stockholm on 13 January 2010, to carry out a directed new share issue with deviation from the shareholders’ preferential rights, subject to approval at the extraordinary general meeting, of in total 5,434,800 shares in order to raise SEK 150 million before transaction expenses. The subscription price is set to SEK 27.60 per share representing a 0.6 percent discount to the one month volume weighted average closing price prior to the Board of Directors’ resolution to issue new shares.
